research funding database


Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

Share this post

ERC webinar 2024
ERC webinar 2024

The Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) funding from the National Institutes of Health (NIH) supports efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The program seeks to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning. Applications are open to researchers at research institutions in the USA, including foreign components of US institutions. Applications are also open to small businesses and for-profit organizations in the USA. Applicants may apply for up to 275,000 USD, plus indirect costs for up to 2 years.

Opportunity number: RFA-TR-23-016

The next letters of intent are due: May 1, 2025. Applications are due: June 2, 2025.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
monthly funding newsletter

unsubscribe at any time